US-based laboratory services provider Labcorp has launched Test Finder, an advanced generative AI tool designed to optimise the selection of laboratory tests.
Labcorp developed Test Finder in collaboration with Amazon Web Services (AWS).
The tool allows healthcare providers to ask questions or describe conditions in plain language to receive curated test recommendations.
It aims to enhance user experience and allocate more time for patient care.
Labcorp chief medical and scientific officer Brian Caveney said: “Clinicians are under increasing pressure to do more with less.
“Test Finder is designed to ease that burden by providing a faster, more intuitive way to navigate complex test menus, conduct research and identify the right tests, so clinicians can focus on what matters most: their patients.”
Currently accessible 24/7 on Labcorp.com, Test Finder leverages Amazon Bedrock and large language model technology, ensuring faster and more efficient test selection.
The tool offers providers a detailed list of suggested tests and descriptions based on their input, covering areas like oncology, women’s health, neurology, and autoimmune diseases.
AWS global chief medical officer Dr. Rowland Illing said: “Labcorp’s AI implementation underscores the transformative power of responsible generative AI in healthcare, setting a new industry standard for clinical workflow optimisation.
“By leveraging AWS’ enterprise-grade AI infrastructure and HIPAA-compliant security controls, Labcorp is revolutionising how healthcare providers access comprehensive diagnostic information, enabling faster decisions that can directly impact patient care outcomes.”
Recently, Labcorp has received the CE mark for the PGDx elio tissue complete solution under the European Union’s new In Vitro Diagnostic Regulation.
The next-generation sequencing (NGS) based diagnostic device enhances personalised cancer care by analysing DNA from formalin-fixed paraffin-embedded tumour tissue.
It is designed to detect gene alterations across 505 genes for pan-solid tumours.
Also, the company has agreed to acquire select ambulatory outreach laboratory service assets from Community Health Systems (CHS) for $195m in cash.
